Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen R Johnston

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
NPJ Breast Cancer|November 29, 2022
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancerSunil Pancholi, Nikiana Simigdala, Ricardo Ribas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 15, 2018
Geographic Variation in Postoperative Imaging for Low-Risk Breast CancerBenjamin L Franc, Timothy P Copeland, Robert Thombley, et al.
Breast Cancer Research : BCR|October 19, 2012
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivoLesley-Ann Martin, Sunil Pancholi, Ian Farmer, et al.
Breast Cancer Research : BCR|February 2, 2020
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancerSunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, et al.
Breast Cancer Research : BCR|June 9, 2018
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancerRicardo Ribas, Sunil Pancholi, Aradhana Rani, et al.
Breast Cancer Research : BCR|December 6, 2019
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancerSunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, et al.
Plos Medicine|December 7, 2016
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- VinorelbineGerald Goh, Ramona Schmid, Kelly Guiver, et al.
Oncogene|April 21, 2020
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalitiesSunil Pancholi, Ricardo Ribas, Nikiana Simigdala, et al.
NPJ Breast Cancer|June 19, 2020
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemicMitch Dowsett, Matthew J Ellis, J Michael Dixon, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
NPJ Breast Cancer|November 29, 2022
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancerSunil Pancholi, Nikiana Simigdala, Ricardo Ribas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 15, 2018
Geographic Variation in Postoperative Imaging for Low-Risk Breast CancerBenjamin L Franc, Timothy P Copeland, Robert Thombley, et al.
Breast Cancer Research : BCR|October 19, 2012
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivoLesley-Ann Martin, Sunil Pancholi, Ian Farmer, et al.
Breast Cancer Research : BCR|February 2, 2020
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancerSunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, et al.
Breast Cancer Research : BCR|June 9, 2018
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancerRicardo Ribas, Sunil Pancholi, Aradhana Rani, et al.
Breast Cancer Research : BCR|December 6, 2019
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancerSunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, et al.
Plos Medicine|December 7, 2016
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- VinorelbineGerald Goh, Ramona Schmid, Kelly Guiver, et al.
Oncogene|April 21, 2020
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalitiesSunil Pancholi, Ricardo Ribas, Nikiana Simigdala, et al.
NPJ Breast Cancer|June 19, 2020
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemicMitch Dowsett, Matthew J Ellis, J Michael Dixon, et al.
Pageof 2